<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>新浪医药 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-05T23:28:08+08:00</updated>
  <subtitle>新浪医药新闻为医药行业从业者提供新鲜全面的医药资讯、权威的医药政策专家解读、药企药店医院新药新闻资讯动态，以及畅所欲言的专栏平台。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>冠脉支架国采结果出炉！中选均价700元，微创、乐普股价跳水</title>
    <updated>2020-11-05T15:54:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-05:/s/E1A4SQYn0xEeIYSBD_Lm2w</id>
    <link href="https://mp.weixin.qq.com/s/E1A4SQYn0xEeIYSBD_Lm2w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>浪眼探会丨第三届进博的“亮眼明星”来啦！看全球医药巨头们的花式battle</title>
    <updated>2020-11-05T15:54:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-05:/s/-aFTJr9aYgru14XYTJOO3g</id>
    <link href="https://mp.weixin.qq.com/s/-aFTJr9aYgru14XYTJOO3g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>速读社丨诺华奥法妥木单抗在中国申报上市 恒瑞提交3类罂粟乙碘油注射液上市申请</title>
    <updated>2020-11-05T15:54:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-05:/s/Iogduh_KcNE9nPKE5BSJKQ</id>
    <link href="https://mp.weixin.qq.com/s/Iogduh_KcNE9nPKE5BSJKQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新一轮医保灵魂砍价将至，378个独家产品有望通过谈判进入，T药、九期一...</title>
    <updated>2020-11-04T18:12:52+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-04:/s/QAo40qqit_Ewif-yk7WoyQ</id>
    <link href="https://mp.weixin.qq.com/s/QAo40qqit_Ewif-yk7WoyQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Celltrion修美乐生物类似药CT-P17在类风湿关节炎的治疗中显示出顶级疗效</title>
    <updated>2020-11-04T18:12:52+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-04:/s/y9exA68xApPyS1W1FC-KFg</id>
    <link href="https://mp.weixin.qq.com/s/y9exA68xApPyS1W1FC-KFg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>速读社丨罗氏Tecentriq联合Avastin疗法在欧获批 豪森NASH新药启动临床</title>
    <updated>2020-11-04T18:12:52+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-04:/s/g4vHFjeGPL04XMqTuvT4cg</id>
    <link href="https://mp.weixin.qq.com/s/g4vHFjeGPL04XMqTuvT4cg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>重磅推荐！2020新浪医药年度总评榜报名开启</title>
    <updated>2020-11-03T17:57:57+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-03:/s/c_f2iF3jdHlGgBc898yzzg</id>
    <link href="https://mp.weixin.qq.com/s/c_f2iF3jdHlGgBc898yzzg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>药明巨诺上市首日盘中破发，手握CAR-T产品，上半年亏损6.5亿</title>
    <updated>2020-11-03T17:57:57+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-03:/s/G6GRHvc7pLsR6M6lOJyvOw</id>
    <link href="https://mp.weixin.qq.com/s/G6GRHvc7pLsR6M6lOJyvOw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>因多名患者死亡，再生元紧急停止Garetosmab临床试验</title>
    <updated>2020-11-03T17:57:57+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-03:/s/iMPxEVELDP-mpJCwSHkzxQ</id>
    <link href="https://mp.weixin.qq.com/s/iMPxEVELDP-mpJCwSHkzxQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>速读社丨罗氏抗流感新药上市申请拟纳入优先审评 辉瑞投资$3.5亿升级爱尔兰工厂</title>
    <updated>2020-11-03T17:57:57+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-03:/s/4JAyDqvO1Ip5BaMAbt2JXw</id>
    <link href="https://mp.weixin.qq.com/s/4JAyDqvO1Ip5BaMAbt2JXw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国家医保局发文推进“互联网+”医疗服务医保支付工作</title>
    <updated>2020-11-02T16:50:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-02:/s/5pokxtFqx0L20wkqzyf75g</id>
    <link href="https://mp.weixin.qq.com/s/5pokxtFqx0L20wkqzyf75g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>速读社丨诺华建立首个亚洲CAR-T生产设施 正大天晴即将拿下泊马度胺首仿</title>
    <updated>2020-11-02T16:50:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-02:/s/13s9Ntg6ObRycZDF2sl-MA</id>
    <link href="https://mp.weixin.qq.com/s/13s9Ntg6ObRycZDF2sl-MA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>政·解 | 地方集采“花式降价”，DIP付费试点登场，耗材国采打响第一枪</title>
    <updated>2020-11-01T17:47:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-01:/s/DXYjWSizf3fgZbBKakep0Q</id>
    <link href="https://mp.weixin.qq.com/s/DXYjWSizf3fgZbBKakep0Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>时评：透景生命一审胜雅培，是国产IVD的胜利吗？</title>
    <updated>2020-11-01T17:47:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-01:/s/4SWDXu0GGsRz7x3x7NL8EQ</id>
    <link href="https://mp.weixin.qq.com/s/4SWDXu0GGsRz7x3x7NL8EQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>速读社丨又一家外企取消销售指标，索马鲁肽治疗NASH获突破性疗法认定</title>
    <updated>2020-11-01T17:47:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-01:/s/9zrb1NvFIG77KBR8bykWsA</id>
    <link href="https://mp.weixin.qq.com/s/9zrb1NvFIG77KBR8bykWsA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>一周药闻丨吉利德停止3项filgotinib试验，抗体偶联药物Enhertu治疗胃癌获FDA优先审评</title>
    <updated>2020-10-30T20:09:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-30:/s/xNzwg3SkYwpQRu_hiZ-v9A</id>
    <link href="https://mp.weixin.qq.com/s/xNzwg3SkYwpQRu_hiZ-v9A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>产业周报丨第三批临床急需境外新药公示，质肽生物完成￥1亿元融资</title>
    <updated>2020-10-30T20:09:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-30:/s/4BQ-sdi1dOJewb-IBXnNGg</id>
    <link href="https://mp.weixin.qq.com/s/4BQ-sdi1dOJewb-IBXnNGg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020 DIA现场丨生物类似药或成企业“弯道超车”捷径，背后两类难题待解</title>
    <updated>2020-10-30T17:58:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-30:/s/_hK0kFwYSmxdG_U0FhBxaw</id>
    <link href="https://mp.weixin.qq.com/s/_hK0kFwYSmxdG_U0FhBxaw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>3年限期将至，莎普爱思旗下滴眼液面临停产风险，公司前三季度亏损2805万元</title>
    <updated>2020-10-30T17:58:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-30:/s/2npbQw6PCILL94aSpEhz4w</id>
    <link href="https://mp.weixin.qq.com/s/2npbQw6PCILL94aSpEhz4w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>速读社丨礼来$4.4亿引进复星医药BCL-2抑制剂 赛诺菲/再生元PD-L1获FDA优先审评</title>
    <updated>2020-10-30T17:58:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-30:/s/iJ0AcQp_eKPHsz88jzYqMQ</id>
    <link href="https://mp.weixin.qq.com/s/iJ0AcQp_eKPHsz88jzYqMQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>